Globus Medical (GMED) Projected to Post Quarterly Earnings on Thursday

Globus Medical (NYSE:GMED) is expected to be announcing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Globus Medical to announce earnings of $1.20 per share and revenue of $792.41 million for the quarter. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. The company had revenue of $789.61 million during the quarter, compared to the consensus estimate of $782.88 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.86 EPS. On average, analysts expect Globus Medical to post $4.99 EPS for the current fiscal year and $5.39 EPS for the next fiscal year.

Globus Medical Trading Up 0.3%

Shares of NYSE:GMED opened at $81.12 on Thursday. The stock has a 50 day moving average of $77.90 and a 200 day moving average of $83.63. The company has a market cap of $10.89 billion, a PE ratio of 20.75, a price-to-earnings-growth ratio of 1.31 and a beta of 0.96. Globus Medical has a 12-month low of $59.51 and a 12-month high of $101.40.

Insider Activity at Globus Medical

In other Globus Medical news, Director Stephen T. Zarrilli sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the sale, the director directly owned 25,000 shares of the company’s stock, valued at $2,176,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director James Tobin sold 30,000 shares of Globus Medical stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the sale, the director owned 15,000 shares in the company, valued at approximately $1,118,700. The trade was a 66.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 18.38% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on GMED shares. UBS Group assumed coverage on shares of Globus Medical in a report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price target on the stock. Wells Fargo & Company reduced their price objective on shares of Globus Medical from $103.00 to $99.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. BMO Capital Markets began coverage on shares of Globus Medical in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 price objective for the company. Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 10th. Finally, BTIG Research restated a “neutral” rating on shares of Globus Medical in a research note on Friday, September 18th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $99.46.

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.